{"doi":"10.1136/bcr-2016-218308","title":"Risk of cumulative toxicity after complete melanoma response with pembrolizumab","abstract":"<jats:p>Pembrolizumab is an approved first-line systemic therapy for unresectable metastatic melanoma. Despite the achievement of complete and durable responses in a small subgroup of patients, it is standard practice that pembrolizumab therapy continues beyond complete response. Nevertheless, the incidence of immune-related toxicities gradually increases with continuing pembrolizumab therapy. We report a case highlighting the occurrence of serious induced immune-related adverse events, which were attributed to pembrolizumab in a patient with metastatic melanoma who obtained a complete response (CR) after receiving pembrolizumab for a total of 6.5 months. Although mild pembrolizumab-related toxicity persists, the patient remains disease-free 5.5 months after discontinuation of pembrolizumab. Accordingly, we believe that cessation of pembrolizumab should be considered in patients who achieve a CR because of the ongoing risk of toxicity with extended pembrolizumab administration.</jats:p>","journal":"BMJ Case Reports","year":2017,"id":594185,"datarank":0.32958368660043297,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.0,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1520942,"name":"Sarah Faithfull","orcid":null,"position":1,"is_corresponding":false},{"id":1520943,"name":"Michael P Brown","orcid":null,"position":2,"is_corresponding":false},{"id":1520941,"name":"Amy Hsin-Chieh Hsieh","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Risk of cumulative toxicity after complete melanoma response with pembrolizumab","abstract":"<jats:p>Pembrolizumab is an approved first-line systemic therapy for unresectable metastatic melanoma. Despite the achievement of complete and durable responses in a small subgroup of patients, it is standard practice that pembrolizumab therapy continues beyond complete response. Nevertheless, the incidence of immune-related toxicities gradually increases with continuing pembrolizumab therapy. We report a case highlighting the occurrence of serious induced immune-related adverse events, which were attributed to pembrolizumab in a patient with metastatic melanoma who obtained a complete response (CR) after receiving pembrolizumab for a total of 6.5 months. Although mild pembrolizumab-related toxicity persists, the patient remains disease-free 5.5 months after discontinuation of pembrolizumab. Accordingly, we believe that cessation of pembrolizumab should be considered in patients who achieve a CR because of the ongoing risk of toxicity with extended pembrolizumab administration.</jats:p>","is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28148549","pmcid":"PMC5294005","openalex_id":"https://openalex.org/W2585407512","authors":[],"funders":[],"total_grants":0,"fwci":0.5794,"citation_percentile":0.68141802,"influential_citations":0,"citation_trend":[{"year":2017,"count":1},{"year":2018,"count":1},{"year":2019,"count":1},{"year":2020,"count":2},{"year":2021,"count":1},{"year":2022,"count":1},{"year":2025,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://syndication.highwire.org/content/doi/10.1136/bcr-2016-218308","host_type":"publisher"},{"url":"https://doi.org/10.1136/bcr-2016-218308","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28148549","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5294005","host_type":"repository"},{"url":"http://casereports.bmj.com/cgi/content/short/2017/feb01_1/bcr2016218308","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","CAR-T cell therapy research","Melanoma and MAPK Pathways","Aged","Antibodies, Monoclonal, Humanized","Antineoplastic Agents","Drug Eruptions","Groin","Hormone Replacement Therapy","Humans","Hydrocortisone","Hypopituitarism","Limbic Encephalitis","Lymphatic Metastasis","Magnetic Resonance Imaging","Male","Melanoma","Pelvis","Thyroxine","Combined Pituitary Hormone Deficiency"],"mesh_terms":["Aged","Antineoplastic Agents","Drug Eruptions","Groin","Humans","Hydrocortisone","Hypopituitarism","Lymphatic Metastasis","Magnetic Resonance Imaging","Male","Melanoma","Pelvis","Thyroxine","Hormone Replacement Therapy","Limbic Encephalitis","Antibodies, Monoclonal, Humanized"],"keywords":["Pembrolizumab","Medicine","Discontinuation","Adverse effect","Metastatic melanoma","Melanoma","Ipilimumab","Internal medicine","Oncology","Immunotherapy","Cancer","Cancer research"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T13:48:52.624267Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}